Abstract
Myocardial Infarction (MI) with Non-obstructive Coronary Arteries (MINOCA) is a syndrome with underlying many causes. MINOCA incidence is estimated to be between 5% and 25% of all MI. The outcome is extremely variable depending on the MINOCA cause. Clinical history, laboratory tests, echocardiography and coronary angiography are the first line diagnostic investigations. Nevertheless, further tests are frequently necessary (e.g. optical coherence tomography, invasive provocative test with acetylcholine or cardiac magnetic resonance) to establish the exact cause, and allowing the adequate risk stratification and management. This is crucial since many patients, particularly those with angiographically normal coronary arteries, are often labelled as ‘noncardiac', therefore missing the chance for appropriate treatment. And this group of patients characterizes substantially worse outcome than previously it was believed. Here, we have reviewed the pathogenesis, diagnosis, prognosis, and management of MINOCA caused by coronary vasospasm or coronary microcirculation dysfunction.
Keywords: Variant angina, coronary spasm, vasospasm, acetylcholine, myocardial infarction with non-obstructive coronary arteries, coronary angiography.
Current Pharmaceutical Design
Title:Advances in Mechanisms and Treatment Options of MINOCA Caused by Vasospasm or Microcirculation Dysfunction
Volume: 24 Issue: 4
Author(s): Jacek Bil*, Natalia Pietraszek, Tomasz Pawlowski and Robert J. Gil
Affiliation:
- Department of Invasive Cardiology, Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw,Poland
Keywords: Variant angina, coronary spasm, vasospasm, acetylcholine, myocardial infarction with non-obstructive coronary arteries, coronary angiography.
Abstract: Myocardial Infarction (MI) with Non-obstructive Coronary Arteries (MINOCA) is a syndrome with underlying many causes. MINOCA incidence is estimated to be between 5% and 25% of all MI. The outcome is extremely variable depending on the MINOCA cause. Clinical history, laboratory tests, echocardiography and coronary angiography are the first line diagnostic investigations. Nevertheless, further tests are frequently necessary (e.g. optical coherence tomography, invasive provocative test with acetylcholine or cardiac magnetic resonance) to establish the exact cause, and allowing the adequate risk stratification and management. This is crucial since many patients, particularly those with angiographically normal coronary arteries, are often labelled as ‘noncardiac', therefore missing the chance for appropriate treatment. And this group of patients characterizes substantially worse outcome than previously it was believed. Here, we have reviewed the pathogenesis, diagnosis, prognosis, and management of MINOCA caused by coronary vasospasm or coronary microcirculation dysfunction.
Export Options
About this article
Cite this article as:
Bil Jacek*, Pietraszek Natalia , Pawlowski Tomasz and Gil J. Robert , Advances in Mechanisms and Treatment Options of MINOCA Caused by Vasospasm or Microcirculation Dysfunction, Current Pharmaceutical Design 2018; 24 (4) . https://dx.doi.org/10.2174/1381612824666180108121253
DOI https://dx.doi.org/10.2174/1381612824666180108121253 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Adjuvant Therapies in Primary Coronary Interventions: Bivalirudin
Cardiovascular & Hematological Agents in Medicinal Chemistry Secondary Stroke Prevention with Antithrombotic Drugs
Current Vascular Pharmacology Anti-platelet Drug-loaded Targeted Technologies for the Effective Treatment of Atherothrombosis
Current Drug Targets Phycobilins and Phycobiliproteins Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry Paclitaxel Formulations: Challenges and Novel Delivery Options
Current Drug Delivery Candidate Circulating Biomarkers for the Cardiovascular Disease Continuum
Current Pharmaceutical Design Does Caffeine Affect Cardiovascular Responses?
Vascular Disease Prevention (Discontinued) Exploring the Potential of NO-Independent Stimulators and Activators of Soluble Guanylate Cyclase for the Medical Treatment of Erectile Dysfunction
Current Pharmaceutical Design Recent Advances in the Development of Selective CB2 Agonists as Promising Anti-Inflammatory Agents
Current Medicinal Chemistry Natriuretic Peptide Testing in Primary Care
Current Cardiology Reviews Anticonvulsant and Antinociceptive Actions of Novel Adenosine Kinase Inhibitors
Current Topics in Medicinal Chemistry Stem Cell Therapy for the Treatment of Acute Myocardial Infarction and Chronic Ischemic Heart Disease
Current Pharmaceutical Biotechnology Cardiovascular Alterations After Spinal Cord Injury: An Overview
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Dietary and Plant Polyphenols Exert Neuroprotective Effects and Improve Cognitive Function in Cerebral Ischemia
Recent Patents on Food, Nutrition & Agriculture Lipoxygenase: An Emerging Target for Stroke Therapy
CNS & Neurological Disorders - Drug Targets Late Sodium Current Inhibition: The Most Promising Antiarrhythmic Principle in the Near Future?
Current Medicinal Chemistry Stent Thrombosis and Duration of Dual Antiplatelet Therapy
Current Pharmaceutical Design The Role of Thiols in Liver Ischemia-Reperfusion Injury
Current Pharmaceutical Design Regulation of Cardiac Nerves: A New Paradigm in The Management of Sudden Cardiac Death?
Current Medicinal Chemistry Inflammatory Mechanisms in Atherosclerosis: The Impact of Matrix Metalloproteinases
Current Topics in Medicinal Chemistry